{"result": "(\"entity\"<|>SOMATOSTATINA<|>EVENT<|>Somatostatin is a hormone that inhibits the secretion of other hormones and is used in medical treatments to reduce lymphatic flow and gastrointestinal secretions.)\n##\n(\"entity\"<|>OCTREOTIDA<|>EVENT<|>Octreotide is a synthetic analog of somatostatin used in various medical treatments, including those for conditions like quilotórax and ascitis quilosa.)\n##\n(\"entity\"<|>DRENAJE INTERMITENTE<|>EVENT<|>Intermittent drainage is a therapeutic procedure used to manage conditions like quilotórax by removing excess fluid from the pleural cavity.)\n##\n(\"entity\"<|>SHUNT PORTOSISTÉMICO TRANSYUGULAR INTRAHEPÁTICO<|>EVENT<|>Transjugular intrahepatic portosystemic shunt (TIPS) is a medical procedure used to treat complications of portal hypertension, including quilotórax.)\n##\n(\"relationship\"<|>SOMATOSTATINA<|>OCTREOTIDA<|>Somatostatin and octreotide are related as octreotide is a synthetic form of somatostatin used in medical treatments<|>8)\n##\n(\"relationship\"<|>QUILOTÓRAX<|>SOMATOSTATINA<|>Somatostatin is used in the treatment of quilotórax to reduce lymphatic flow<|>6)\n##\n(\"relationship\"<|>QUILOTÓRAX<|>OCTREOTIDA<|>Octreotide is used in the management of quilotórax to help decrease fluid accumulation<|>6)\n##\n(\"relationship\"<|>QUILOTÓRAX<|>DRENAJE INTERMITENTE<|>Intermittent drainage is a treatment option for managing quilotórax by removing excess fluid<|>7)\n##\n(\"relationship\"<|>QUILOTÓRAX<|>SHUNT PORTOSISTÉMICO TRANSYUGULAR INTRAHEPÁTICO<|>TIPS can be utilized in the treatment of quilotórax secondary to portal hypertension<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: .5®                       18         49          33         70                  1,5\n                    (Abbott)\n                    Alitraq®                                 21         65          14         53                  1\n                    (Abbott)\n                  CHO: carbohidratos; L: lípidos; P: proteínas; TCM: triglicéridos de cadena media.\n                  * Fórmulas de uso pediátrico.\n\n\n\nseguir el cierre de la fístula quilosa, o que la patología                      TCM (50% de TCM y 50% de TCL) o emulsiones con dis-\nsubyacente requiera una intervención nutricional más                            tintos porcentajes de TCM y TCL (lípidos estructurados).\nagresiva. Su indicación también se ha recomendado en                              Cuando se inicia la NP, esta debería mantenerse por un\npacientes con importantes pérdidas que han sido tra-                            período mínimo de 2-3 semanas para conseguir una me-\ntados con cirugía abdominal.                                                    joría clínica. La tasa de resolución de ascitis quilosa posto-\n   El fundamento de la indicación de la NP es que per-                          peratoria o quilotórax puede oscilar del 60 al 100% con\nmitiría el reposo digestivo, la reducción del flujo es-                         NP. Los pacientes con NP pueden mantener la ingestión\nplácnico y secundariamente del flujo quiloso. Al mismo                          de líquidos sin grasa, con alimentos naturales o fórmulas\ntiempo permitiría una rápida corrección de los des-                             nutricionales sin grasa por vía oral sin que esto suponga\nequilibrios electrolíticos.                                                     un incremento del flujo linfático, al mismo tiempo que\n   La NP se debe ajustar a las necesidades energéticas y                        permitiría mantener el trofismo intestinal20-26, 32, 33.\nproteicas según la situación clínica del paciente. En su\nformulación puede incorporar lípidos a base de TCL y                            5.1.4.    Tratamiento farmacológico\nTCM, puesto que la infusión se realiza a través de una\nvena central o periférica sin influir en el flujo linfático. Ac-                  La somatostatina y su análogo la octreotida, en com-\ntualmente se dispone de diferentes tipos de emulsiones                          binación con NP o con la dieta baja en grasa y suple-\npara la administración parenteral, las mezclas físicas de                       mentada con TCM, reducen de forma importante el\n---\n                                              Tema 21.     Quilotórax y ascitis quilosa. Dietas modificadas en triglicéridos…                 361\n\n\n\nflujo linfático y ejercen un efecto beneficioso en la reso-                     caso de quilotórax, o el shunt peritoneovenoso en la\nlución del quilotórax y las fístulas linfáticas20, 23, 24, 33-39.               ascitis quilosa. En última instancia, el cateterismo ex-\n   El mecanismo por el cual la somatostatina y la octreoti-                     terno para drenaje intermitente puede ser una alterna-\nda disminuyen el flujo linfático y la producción de quilo                       tiva terapéutica a considerar en los casos refractarios.\npodría atribuirse a la reducción de las secreciones gastroin-                     A pesar del tratamiento agresivo de las fístulas quilo-\ntestinales, del flujo esplácnico y de la absorción intestinal                   sas, las reintervenciones para su corrección pueden in-\nde grasas junto a un aumento de la excreción de grasas.                         crementar notablemente la morbimortalidad.\n   Aunque hay series de casos con este tratamiento, su\nuso es controvertido. No hay indicación para el quilo-                          5.3.   Tratamiento con radiología intervencionista\ntórax, ni la dosis ni la duración del tratamiento ha sido\nestandarizada por ensayos clínicos. De todas formas, si                           Actualmente existen diversos tratamientos radiológi-\nun drenaje que se mantenía estable se reduce a la mi-                           cos intervencionistas que pueden ser aplicados en los\ntad en las 48h del inicio de la administración de octreo-                       casos de quilotórax o fístulas linfáticas traumáticas y\ntida o somatostatina, sugiere que hay una buena res-                            no traumáticas, aunque no están disponibles en todos\npuesta y debería mantenerse el tratamiento.                                     los centros.\n   Otro tratamiento farmacológico es la etilnefrina20, 39,                        El  shunt portosistémico transyugular intrahepático\nfármaco simpaticomimético que reduce el flujo linfáti-                          (TIPS) 40 es de utilidad en el quilotórax secundario a\nco en el conducto torácico por contracción de la mus-                           hipertensión portal que puede resolverlo espontá\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>ABBOTT<|>ORGANIZATION<|>Abbott is a healthcare company that develops and provides various medical products and services, including nutritional solutions and pharmaceuticals.)\n##\n(\"entity\"<|>TCM<|>EVENT<|>TCM refers to medium-chain triglycerides, which are a type of fat used in nutritional formulations for patients requiring specialized dietary management.)\n##\n(\"entity\"<|>TCL<|>EVENT<|>TCL refers to long-chain triglycerides, which are another type of fat used in nutritional formulations.)\n##\n(\"entity\"<|>QUILOTÓRAX<|>EVENT<|>Quilotórax is a medical condition characterized by the accumulation of lymphatic fluid in the pleural cavity, often requiring nutritional intervention and treatment.)\n##\n(\"entity\"<|>ASCITIS QUILOSA<|>EVENT<|>Ascitis quilosa is a condition involving the accumulation of chyle in the abdominal cavity, often treated with nutritional support and medical interventions.)\n##\n(\"relationship\"<|>ABBOTT<|>TCM<|>Abbott develops nutritional products that incorporate TCM for patients with specific dietary needs<|>7)\n##\n(\"relationship\"<|>ABBOTT<|>TCL<|>Abbott provides nutritional solutions that include TCL for patients requiring dietary management<|>7)\n##\n(\"relationship\"<|>QUILOTÓRAX<|>ASCITIS QUILOSA<|>Quilotórax and ascitis quilosa are both conditions that may require similar nutritional interventions and treatments<|>5)\n<|COMPLETE|>"}]}